Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Setmelanotide
Also known as: IMCIVREE, RM-493, setmelanotide acetate
Eighty percent of POMC-deficient patients lost at least 10% of their body weight at one year. For a population with zero prior treatment options and lifelong unrelenting hunger, that number landed differently. Setmelanotide (IMCIVREE) is an 8-amino-acid cyclic peptide that directly activates the melanocortin-4 receptor in the hypothalamus, restoring the satiety signal these patients were born without. It earned FDA approval in November 2020 for POMC, PCSK1, and LEPR deficiency obesity, expanded to Bardet-Biedl syndrome in 2022, and picked up acquired hypothalamic obesity in March 2026. This drug does not work for common obesity. It replaces a missing molecular signal, not a behavioral one.
What Is Setmelanotide?
Mean body weight dropped 25.6% in POMC-deficient patients at 52 weeks (Clement et al. 2020, n=21)[1]. LEPR-deficient patients saw 12.5%. These are patients who experienced pathological, constant hunger from birth with no effective treatment until setmelanotide arrived.
Setmelanotide (brand name IMCIVREE, CAS 920014-72-8) is a cyclic 8-amino-acid peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). It is a selective agonist at MC4R in the hypothalamus, the receptor that normally receives alpha-MSH to trigger satiety. In patients with POMC, PCSK1, or LEPR deficiency, the upstream pathway producing that alpha-MSH signal is broken. Setmelanotide steps in as a synthetic replacement, directly activating the receptor these patients can't reach on their own.
The approved patient population keeps expanding. November 2020 brought initial approval for POMC, PCSK1, and LEPR deficiency obesity in patients aged 6 and older. Bardet-Biedl syndrome followed in 2022 (Haqq et al., n=44)[2]. The VENTURE trial (n=12)[3] extended approval down to age 2 in December 2024. Most recently, the TRANSCEND Phase 3 (n=120) secured acquired hypothalamic obesity approval in March 2026, showing an 18.4% placebo-adjusted BMI reduction.
Specificity is the defining characteristic. Phase 2 trials in non-syndromic obesity showed minimal results. The EMANATE trial in March 2026 failed all four primary endpoints in heterozygous variant carriers. Setmelanotide works when the MC4R pathway is genuinely broken, not when it's functioning normally.
How Setmelanotide Works
In normal physiology, leptin activates POMC neurons in the arcuate nucleus of the hypothalamus. Those neurons produce alpha-MSH, which travels to the paraventricular nucleus and binds MC4R. That binding event triggers satiety and increases energy expenditure. The entire cascade depends on each link working; a genetic defect at POMC, PCSK1, or LEPR breaks the chain before alpha-MSH ever reaches MC4R.
Setmelanotide bypasses every upstream defect. It binds MC4R directly, restoring the satiety signal regardless of whether the patient can produce functional leptin responses, POMC protein, or processed alpha-MSH. The cyclic disulfide-bridged structure gives it proteolytic stability that native alpha-MSH lacks.
Selectivity is relative. Setmelanotide activates MC4R preferentially, but it also hits MC1R on melanocytes and MC3R to a lesser degree. MC1R activation drives melanin production, which is why roughly 61 to 83% of treated patients develop skin hyperpigmentation. That side effect is mechanistic and expected; it reverses after stopping treatment.
Plasma half-life sits at approximately 11 hours (FDA label, Section 12.3). Protein binding is 79.1%, with a volume of distribution around 49 to 75 L. Steady-state concentration is reached within about 2 days of daily dosing. The drug is cleared through proteolytic catabolism rather than CYP enzyme metabolism, which keeps the drug interaction profile low.
Setmelanotide Benefits
- Setmelanotide benefits center on restoring satiety in patients with specific genetic defects in the melanocortin pathway.
- Only FDA-approved therapy targeting MC4R for POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity. No alternative treatments exist for these populations.
- Mean 25.6% body weight reduction at 52 weeks in POMC-deficient patients, with 80% achieving at least 10% weight loss (Clement et al. 2020, n=21)[1].
- Hunger score reduction of 27 to 44% in clinical trials. Caregivers describe children feeling satiated for the first time in their lives; quality of life improvements were detectable by week 5 in trial data.
- Approved down to age 2 following the VENTURE trial (n=12)[3], where 83% of children achieved a clinically meaningful BMI Z-score reduction at 52 weeks.
- The TRANSCEND Phase 3 (n=120) delivered an 18.4% placebo-adjusted BMI reduction in acquired hypothalamic obesity, opening treatment to patients with craniopharyngioma-related or trauma-related hypothalamic injury.
- No tolerance or tachyphylaxis observed in any trial through the longest follow-up periods. Open-label extension and real-world cohort data (n=17, mean 14.4 months)[4] confirm durable appetite suppression.
Setmelanotide: Science vs Community Consensus
FDA-approved for POMC/PCSK1/LEPR deficiency obesity, Bardet-Biedl syndrome, and (March 2026) acquired hypothalamic obesity.
Read the evidence (key study, limitations)
Phase 3 data in confirmed-genetic patients: mean −25.6% weight at 52 weeks (POMC deficiency), −12.5% (LEPR deficiency), −18.4% placebo-adjusted BMI (hypothalamic obesity). Efficacy is strictly limited to approved genetically confirmed or injury-defined populations: fails in common polygenic obesity and failed EMANATE heterozygous substudies (March 2026).
Clement et al. 2020 (PMID 33137293): Phase 3, POMC/LEPR deficiency, n=21; 80% of POMC patients achieved ≥10% weight loss at 52 wks, mean −25.6%. Haqq et al. 2022 (PMID 36356613): Phase 3 BBS, n=44; 44.4% achieved ≥10% weight loss vs 0% placebo. VENTURE (PMID 39549719, Lancet DE 2025): n=12 ages 2–5; 83% achieved ≥0.2 BMI-Z reduction at 52 wks. TRANSCEND (2026): hypothalamic obesity n=120; −18.4% placebo-adjusted BMI.
Efficacy limited to patients with confirmed pathogenic/likely pathogenic variants in POMC, PCSK1, LEPR, BBS-associated genes, or confirmed hypothalamic injury. No efficacy in common polygenic obesity. EMANATE trial (March 2026) failed all 4 primary endpoints in heterozygous variant carriers (POMC/PCSK1 hets, LEPR hets, SRC1/NCOA1, SH2B1). Trial populations very small due to ultra-rare disease prevalence. Long-term safety beyond 3–4 years limited.
Extremely small online community (ultra-rare patient population: <30 Reddit threads).
Read the reports (what users report 5, common issues 5)
Structured stakeholder data from 41 caregivers (CADTH 2023) shows near-universal positive sentiment; 95% would recommend. Primary complaints are hyperpigmentation, daily injection burden, and insurance/access barriers, not drug effectiveness. No off-label community use documented.
- Patients report feeling satiated for the first time in their lives: described as life-changing by caregivers
- Substantial sustained weight loss with no tolerance observed at 1+ year follow-up
- Quality of life improvements within 5 weeks: improved focus, mobility, social participation
- Reduction in family stress from managing constant food-seeking/hyperphagia behaviors
- Only effective treatment option for this population (no comparator alternatives exist)
- Hyperpigmentation (skin darkening) in ~61–83%: cosmetically distressing, especially in lighter-skinned patients
- Daily injection burden: particularly challenging for vision-impaired BBS patients and young children
- Insurance prior authorization hurdles and extreme cost (~$419K–$429K/year without assistance)
- GI upset (nausea, diarrhea) common during first 2–4 weeks at each dose level
- Lifelong dependency: stopping causes rapid return of hyperphagia and weight regain within days to weeks
Scientific data and community reports are tightly aligned. Both confirm dramatic hunger suppression and significant weight loss in confirmed-genetic patients. Community-reported side effects (hyperpigmentation, GI effects, injection reactions) match clinical trial AE profiles exactly. No community reports of off-label use for common obesity, consistent with clinical findings that it does not work for that indication.
Setmelanotide Dosage Guide
No reconstitution needed. IMCIVREE ships as a ready-to-inject 10 mg/mL solution in multi-dose vials. That's one less variable to manage. If you receive a lyophilized powder claiming to be setmelanotide, it is not the FDA-approved product.
Syringe math for the 10 mg/mL vial using a U-100 insulin syringe: 1 mg equals 10 units (0.1 mL), 2 mg equals 20 units (0.2 mL), 3 mg equals 30 units (0.3 mL). Each vial contains 10 mg total.
Inject in the morning. The 11-hour half-life means drug levels peak around 8 hours post-dose. Morning dosing aligns appetite suppression with daytime eating patterns.
Store unopened vials at 2 to 8 degrees Celsius. Once out of the refrigerator, a vial can stay at 2 to 25 degrees Celsius for up to 30 days, with brief excursions up to 30 degrees Celsius. Discard it 30 days after first opening, regardless of remaining volume.
This drug requires confirmed genetic testing before prescribing. Rhythm Pharmaceuticals provides free genetic testing through their IMCIVREE support program. You can't skip that step; setmelanotide won't help without a confirmed pathogenic variant.
Cycling
No scheduled off period.
Designed for continuous daily use in patients with confirmed genetic obesity. Discontinuation leads to return of hyperphagia and weight regain. Treatment is lifelong in responders.
Setmelanotide is not cycled. It is a chronic replacement therapy providing the MC4R signal that patients are constitutionally missing (genetic indications) or have lost (hypothalamic injury). Continuous daily dosing is required to maintain appetite suppression. Stopping causes rapid return of pathological hyperphagia and weight regain: typically within days to weeks. There is no receptor desensitization, antibody formation, hormonal axis suppression, or safety-monitoring concern that would necessitate cycling. Cycling would be therapeutically counterproductive.
- Rapid return of constant hunger/hyperphagia within days of missed doses or stopping
- Weight regain begins quickly after discontinuation
- Treatment is designed and labeled as lifelong in confirmed responders
Or use the universal Peptide Calculator for any peptide.
Setmelanotide Protocols by Goal
Expected: Mean −25.6% body weight in POMC-deficient patients, −12.5% in LEPR-deficient patients, ~−12% in BBS patients at 52 weeks. Hunger score reduction 27–44%. Efficacy requires confirmed pathogenic/likely pathogenic variant.
Monitor: Baseline skin and eye exam. Monthly weight/BMI. Assess for depression/suicidal ideation at each visit. Evaluate male patients for spontaneous erections (priapism >4 hours = medical emergency). Renal function at baseline. Assess response at week 16.
How to Inject Setmelanotide
- 1Confirm genetic testing results are on file
Setmelanotide requires documented pathogenic or likely pathogenic variants in POMC, PCSK1, LEPR, BBS-associated genes, or confirmed hypothalamic injury.
- 2No reconstitution required
IMCIVREE is a clear, colorless, ready-to-inject 10 mg/mL solution. Inspect visually before each injection; discard if cloudy or discolored.
- 3Draw the correct dose into a U-100 insulin syringe
Adults and adolescents 12 and older: start at 20 units (2 mg, 0.2 mL) daily for 2 weeks. Children 6 to under 12: start at 10 units (1 mg, 0.1 mL). Children 2 to under 6: start at 5 units (0.5 mg, 0.05 mL).
- 4Step 4
Use a 1 mL syringe with a 28 or 29 gauge needle for subcutaneous injection (label section 2.5). Pinch skin at the abdomen, thigh, or upper arm. Insert the needle straight in at a 90-degree angle (IMCIVREE Instructions for Use). Inject slowly. Rotate injection sites with each dose.
- 5Inject once daily in the morning
Appetite suppression onset tracks with Tmax (approximately 8 hours), so morning dosing covers daytime eating hours.
- 6Step 6
After 2 weeks, if the starting dose is tolerated, increase per protocol. Adults and adolescents: increase to 30 units (3 mg, 0.3 mL). Children 6 to under 12: increase to 20 units (2 mg). If 2 mg is tolerated, increase to 30 units (3 mg), the maintenance dose; if not, reduce to 10 units (1 mg) (label section 2.3). Children 2 to under 6: the dose then follows baseline body weight (label Table 3), rising 5 units (0.5 mg) every 2 weeks. It stops at 5 units (0.5 mg) for 15 to under 20 kg and 10 units (1 mg) for 20 to under 30 kg. It stops at 15 units (1.5 mg) for 30 to under 40 kg and 20 units (2 mg) for 40 kg and up.
- 7Assess response at 16 weeks
Discontinue if body weight reduction is less than 5% (adults) or BMI Z-score reduction is inadequate (children) at maximum tolerated dose.
- 8Store unopened vials in the refrigerator
Once out of the refrigerator, keep the vial at 2 to 25 degrees Celsius for up to 30 days, with brief excursions up to 30 degrees Celsius. Discard it 30 days after first opening.
Setmelanotide Stacking Protocols
Works With
Avoid
Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R). Combining with setmelanotide risks additive hyperpigmentation, unpredictable MC4R overstimulation, and additive priapism risk. No clinical safety data on co-administration.
Do not combineMC3R/MC4R agonist. Combining with setmelanotide risks additive transient blood pressure changes, hyperpigmentation, and priapism risk. No clinical data on co-administration.
Do not combineNo clinical evidence for combination benefit. GLP-1s were inadequate monotherapy in POMC/LEPR-deficient patients prior to starting setmelanotide in clinical trials, as the MC4R pathway defect is not addressed by incretin mechanisms. No safety data on combination. Monitoring for additive GI side effects would be required if co-prescribed.
Estimated Cost
Pricing updated 2026-04-09
Setmelanotide Side Effects
Depression and suicidal ideation carry an FDA-labeled warning. Patients must be screened for major depressive disorder at each clinic visit. Pediatric patients and those with acquired hypothalamic obesity (where pre-existing hypothalamic injury may complicate mental health assessment) require particularly close monitoring. This warning is non-negotiable.
Priapism in male patients is a medical emergency. Spontaneous penile erections occur due to MC4R's role in sexual function. An erection lasting 4 hours or more requires urgent urological evaluation; untreated priapism causes permanent vascular damage. If recurring spontaneous erections (under 4 hours) develop, discuss dose reduction with the prescriber.
Skin hyperpigmentation is the most common effect, reported in approximately 61% of trial patients and up to 83% in some datasets. MC1R activation in melanocytes drives melanin production. The darkening is cosmetic, not associated with malignancy, and reverses after stopping treatment. Baseline skin and ophthalmic exams are required before starting. Annual dermatology follow-up monitors pre-existing nevi for changes, as rare reports of darkening of existing moles appear in the prescribing information.
Injection site reactions (erythema, pruritus) affect roughly 48% of patients. Rotating injection sites between abdomen, thigh, and upper arm reduces occurrence over time.
Gastrointestinal symptoms include nausea, diarrhea, and abdominal pain. These are most pronounced during the first 2 to 4 weeks at each dose level. Following the FDA-labeled 2-week titration steps reduces severity. If symptoms are intolerable at 3 mg, remaining at 2 mg is acceptable per label.
Published side effect data comes from Phase 3 trials in ultra-rare patient populations (combined enrollment across trials: approximately 200 patients). Long-term safety data beyond 3 to 4 years remains limited. Caregiver survey data (n=41, CADTH NBK599842) confirms the clinical trial AE profile without adding new safety signals.
Contraindications: known hypersensitivity to setmelanotide or excipients, obesity not caused by approved genetic or hypothalamic indications (will not work), pregnancy (discontinue if pregnancy occurs), and active major depressive disorder or suicidal ideation (monitor closely if initiating).
Kidney function changes the dose. Exposure rises 13 to 96% with renal impairment, and the label lowers the dose when it is severe (eGFR 15 to 29). For BBS or POMC, PCSK1 or LEPR deficiency, the start is 0.5 mg daily. Maintenance is 1.5 mg daily from age 12 and 1 mg daily for ages 6 to under 12. Children 2 to under 6 stay at 0.5 mg if they weigh 20 to under 30 kg; at 30 kg or more they move to 1 mg from week 3. With severe impairment, the label does not recommend it for acquired hypothalamic obesity or for children 2 to under 6 who weigh under 20 kg. IMCIVREE is not recommended at all in end-stage renal disease (eGFR under 15). Mild or moderate impairment needs no change (IMCIVREE label 2.4 and Table 4, 8.6).
When to seek medical attention: erection lasting 4 hours or more (emergency), new or worsening depression or suicidal thoughts, new or changing skin moles, and persistent severe GI symptoms not resolving with dose titration.
Common Issues & Solutions
Hyperpigmentation appears in ~61–83% of patients. It is reversible upon discontinuation, cosmetic only, and not associated with malignancy. Baseline skin and eye exam required before starting; annual dermatology follow-up recommended for monitoring pre-existing nevi. Cannot be prevented: it is mechanistic (MC1R activation).
Priapism (erection lasting ≥4 hours) in male patients is a medical emergency: go to the ER immediately. Do not confuse with milder "spontaneous erections" listed in the FDA label; priapism causes permanent vascular damage if untreated. If spontaneous erections are recurring (but <4 hours), discuss dose reduction with prescriber.
GI symptoms (nausea, diarrhea, abdominal pain) are most common during the first 2–4 weeks at each dose level. Following the FDA 2-week titration steps minimizes severity. If intolerable at 3 mg, remain at 2 mg: there is no requirement to reach maximum dose for efficacy.
Inadequate weight loss (<5% at 16 weeks at maximum tolerated dose): first confirm the genetic diagnosis is appropriate (pathogenic/likely pathogenic variant confirmed by CLIA-certified laboratory). Confirm injection technique and dose accuracy with a specialty pharmacist. Per label, discontinue if confirmed non-responder.
Insurance denial or access barrier: Rhythm InTune patient access program offers free genetic testing, specialty pharmacy navigation, and copay support. Patient assistance programs can reduce cost substantially for eligible patients.
Ask AI about this page
Ask AI for a second opinion on Setmelanotide dosing and side effects
Contraindications
- Known hypersensitivity to setmelanotide or any excipients
- Obesity not caused by POMC, PCSK1, LEPR deficiency, or BBS (will not work in common obesity)
- Pregnancy: discontinue if pregnancy occurs
- Patients with major depressive disorder or active suicidal ideation (monitor closely if initiating)
Drug Interactions
- No formal drug interaction studies have been conducted
- Setmelanotide is cleared by proteolytic catabolism, not CYP enzymes: low risk of metabolic drug interactions
- Caution with drugs that affect melanocortin signaling or cause depression
- Renal impairment: exposure rises 13-96% with severity. In severe impairment (eGFR 15-29) with BBS or POMC, PCSK1 or LEPR deficiency, the label starts at 0.5 mg and maintains at 1.5 mg from age 12 and 1 mg for ages 6 to under 12. Ages 2 to under 6: 0.5 mg at 20 to under 30 kg, 1 mg from week 3 at 30 kg or more, not recommended under 20 kg. Not recommended in acquired hypothalamic obesity with severe impairment or in end-stage renal disease (label 2.4, Table 4)
- Non-selective melanocortin agonist (MC1R, MC3R, MC4R, MC5R). Combining with setmelanotide risks additive hyperpigmentation, unpredictable MC4R overstimulation, and additive priapism risk. No clinical safety data on co-administration.
- MC3R/MC4R agonist. Combining with setmelanotide risks additive transient blood pressure changes, hyperpigmentation, and priapism risk. No clinical data on co-administration.
Product Quality
IMCIVREE is FDA-approved and manufactured as a sterile ready-to-inject 10 mg/mL solution by Rhythm Pharmaceuticals. No compounded versions exist: setmelanotide is not on the FDA shortage list, not on the 503B bulk substances list, and has never been in shortage. No generics. Research-grade setmelanotide (CAS 920014-72-8) is sold only as a lab reagent for research; it is not clinical-grade and is not approved for human use.
- Only use FDA-approved IMCIVREE dispensed by a licensed specialty pharmacy: no compounded or research-grade alternatives are appropriate for clinical use.
- Store unopened vials refrigerated at 2–8°C. Once in use, vials may be kept at room temperature (≤30°C) for up to 30 days.
- Discard vials after 30 days of first use even if solution remains.
- IMCIVREE requires no reconstitution: it is a clear, colorless, ready-to-inject solution. A lyophilized powder would not be the correct product.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Body weight / BMI (BMI Z-score for children) | Monthly throughout treatment | ≥5% body weight reduction by week 16 (adults); adequate BMI Z-score reduction vs. baseline (children) |
| Skin examination (dermatology) | Baseline before starting, then annually | Not listed |
| Ophthalmic examination | Baseline before starting, then annually (especially BBS patients) | Not listed |
| Mental health / depression screening | At each clinic visit throughout treatment | Not listed |
| Hunger score assessment (patient/caregiver Likert scale) | Monthly | Not listed |
| Renal function (eGFR / serum creatinine) | Baseline, then annually or if clinical concern | Not listed |
Primary efficacy endpoint. Discontinue if <5% weight reduction at 16 weeks at maximum tolerated dose (inadequate BMI Z-score reduction in children).
Monitor pre-existing nevi for darkening from MC1R activation. General hyperpigmentation is expected, benign, and reversible; new or changing nevi warrant dermatology evaluation per FDA label.
BBS is associated with retinal dystrophy: baseline documentation and annual monitoring per FDA label. Recommended for all patients; critical for BBS.
FDA labeled warning: depression and suicidal ideation. PHQ-9 or age-appropriate pediatric equivalent. Particularly important in pediatric patients and those with hypothalamic injury (HO indication).
Secondary efficacy marker used in all Phase 3 trials. Validates drug is working on appetite suppression, which often precedes measurable weight loss.
Renal impairment raises setmelanotide AUC 13–96% depending on severity. With severe impairment (eGFR 15 to 29) the FDA label lowers the dose, and it is not recommended below eGFR 15 (label 2.4, 8.6).
Setmelanotide Before and After
Dose titration from 1-2mg to target dose. Appetite suppression begins within the first week. Injection site reactions and early hyperpigmentation may appear.
Noticeable reduction in hunger and food-seeking behavior. Patients and caregivers often report the first time the patient has ever felt full.
Measurable weight loss begins. Skin darkening becomes more apparent. Hunger scores drop 27-44% on average.
Steady weight loss continues: mean 25.6% in POMC patients, 12.5% in LEPR patients at 52 weeks. Quality of life improvements reported as early as week 5.
What to Expect
Days 1 through 14 (Titration): Treatment begins at the starting dose matched to age. Appetite suppression can appear within the first week. GI effects like nausea and diarrhea are most common in this window. Early skin darkening may become visible within 1 to 2 weeks. Caregivers often describe these first days as the most impactful, with reduced food-seeking behavior appearing before measurable weight change.
Weeks 2 through 4: Dose increases to the next level if tolerated. Hunger scores begin dropping measurably. Patients and caregivers frequently describe the first experience of satiety. Mealtime anxiety and constant food preoccupation start to fade. Quality of life improvements are detectable by week 5 in trial data. Weight change isn't dramatic yet; the hunger relief comes first.
Months 1 through 3: Measurable weight loss starts showing on the scale. Hunger scores are down 27 to 44% from baseline on average. Hyperpigmentation becomes more apparent. Children become more engaged in daily activities. Families report improved social interactions and school focus. Skin darkening is the primary cosmetic concern at this stage.
Months 3 through 12: Steady weight loss continues toward the 52-week outcomes. Mean reductions land at 25.6% for POMC patients, 12.5% for LEPR patients, and 18.4% placebo-adjusted BMI for hypothalamic obesity. No tolerance has been observed in any trial. Weight loss typically plateaus between months 9 and 12. In structured caregiver surveys, 95% would recommend setmelanotide.
Year 2 and beyond: Open-label extension data and a real-world cohort study (n=17, mean follow-up 14.4 months)[4] confirm the benefit holds. No tolerance to appetite suppression has developed. Injection routine becomes normalized for families. Annual skin exams for nevi monitoring become part of the routine. Missing doses for extended periods causes rapid return of hyperphagia and weight regain.
Detailed Timeline: Science vs Community
Dose titration at starting dose. Appetite suppression begins within days 1–7. GI side effects (nausea, diarrhea) most common in this window. Early hyperpigmentation may appear. Injection site reactions common.
Caregivers describe the first days as transformative: first signs of reduced food-seeking behavior. Skin darkening noticed within 1–2 weeks. GI nausea manageable with food.
Dose increased to next level if tolerated. Hunger scores begin declining measurably. Food-seeking behaviors reduce. Quality of life improvements detectable by week 5 in trial data.
Caregivers report patients feeling full for the first time in their lives. Reduction in mealtime anxiety and constant food-preoccupation. Weight change not yet dramatic but hunger clearly down.
Measurable BMI and weight reduction begins. Hunger scores down 27–44% from baseline. Hyperpigmentation becomes more apparent. Energy and mobility improving.
Visible weight loss noted. Children more engaged in daily activities. Families report improved social interactions and school focus. Skin darkening is the primary cosmetic concern.
Continued weight loss toward 52-week outcomes (mean −25.6% POMC, −12.5% LEPR, −18.4% HO). No tachyphylaxis or tolerance observed in any trial. Weight loss plateau approached by 9–12 months.
95% of caregivers in structured stakeholder surveys would recommend setmelanotide. Maintained weight loss and hunger suppression at 1 year. Rapid weight regain if doses are missed for extended periods.
Open-label extension data and real-world cohort (PMID 40897637, n=17, mean 14.4 months) confirm durable benefit. No tolerance to appetite suppression observed. Stopping causes rapid hyperphagia return and weight regain.
Injection routine becomes normalized. Quality of life maintained. Annual skin exam for nevi monitoring is accepted part of routine.
Pharmacokinetics
Source: IMCIVREE FDA Prescribing Information, Section 12.3 Pharmacokinetics
Pharmacokinetics: Active Dose Over Time
t½ = ~11 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Setmelanotide Legal?
Setmelanotide is FDA-approved under the brand name IMCIVREE (Rhythm Pharmaceuticals). Initial approval came in November 2020 for POMC, PCSK1, and LEPR deficiency obesity in patients aged 6 and older. Bardet-Biedl syndrome was added in June 2022. The age range expanded to 2 and older in December 2024 following the VENTURE trial. Acquired hypothalamic obesity in patients aged 4 and older was approved in March 2026 per the TRANSCEND Phase 3 results.
IMCIVREE is distributed through specialty pharmacies only. It is not available through standard retail pharmacies or compounding pharmacies. No compounded versions exist; setmelanotide is not on the FDA shortage list or the 503B bulk substances list. Research-grade setmelanotide acetate (CAS 920014-72-8) is sold only as a lab reagent for research and is not appropriate for human use.
Annual cost runs approximately $419,000 to $429,000 at retail. Rhythm InTune patient access program and other patient assistance programs offer financial assistance to eligible patients. WADA status: not currently listed on the prohibited substance list, though athletes should verify with their governing body. This content is for educational purposes only and does not constitute medical advice.
Who Should Consider Setmelanotide
- Patients aged 6+ with genetically confirmed POMC deficiency obesity
- Patients with PCSK1 deficiency obesity
- Patients with LEPR deficiency obesity
- Patients with Bardet-Biedl syndrome (BBS)
- Individuals who have failed all conventional obesity treatments due to monogenic causes
Related Peptides
What Changed for Setmelanotide
- Safety
Corrected Oct 18, 2026: setmelanotide's kidney note now gives the label's lower dose for severe impairment in place of no adjustment, per the Imcivree label.
Before: Renal impairment raises exposure 13-96%: no dose adjustment per label, but monitor After: Severe impairment lowers the label dose (0.5 mg start; 1.5 mg, 1 mg or 0.5 mg maintenance by age and weight); not recommended under 20 kg at ages 2 to under 6, in acquired hypothalamic obesity or in end-stage renal disease
Source: Imcivree (setmelanotide) prescribing information, sections 2.4 (with Table 4) and 8.6 (openFDA label record, SPL version 14, effective Apr 1, 2026; captured as the same-version DailyMed SPL XML, Table 4 image beside it) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 18, 2026: severe kidney impairment cuts setmelanotide to a 0.5 mg start, then 0.5 to 1.5 mg by age and weight, per the Imcivree label.
Before: Renal impairment raises exposure 13 to 96%; no dose adjustment is required per label After: Severe impairment (eGFR 15 to 29): 0.5 mg start; maintenance 1.5 mg from age 12, 1 mg at ages 6 to under 12, and at ages 2 to under 6 0.5 mg (20 to under 30 kg) or 1 mg (30 kg and up); not recommended under 20 kg, in acquired hypothalamic obesity or below eGFR 15
What this does not mean: Mild or moderate kidney impairment still needs no dose change, and the usual doses did not change. Severe impairment was always in the label; the page said no adjustment was needed.
Source: Imcivree (setmelanotide) prescribing information, sections 2.4 (with Table 4) and 8.6 (openFDA label record, SPL version 14, effective Apr 1, 2026; captured as the same-version DailyMed SPL XML, Table 4 image beside it) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 9, 2026: setmelanotide starts at 2 mg daily for BBS and POMC, PCSK1 or LEPR deficiency from age 12, per the Imcivree label.
Before: Beginner 1 mg daily (the start for children aged 6 to under 12) After: Beginner 2 mg daily, with a note that acquired hypothalamic obesity starts at 0.5 mg daily
Source: Imcivree (setmelanotide) prescribing information (openFDA label record, SPL version 14, effective Apr 1, 2026) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations
References
- [1]Phase 3 Trials: Setmelanotide in POMC and LEPR Deficiency Obesity (Clement et al.) (opens in a new tab)(n=21)PubMed (opens in a new tab)PubMed
- [2]Phase 3 Trial: Setmelanotide in Bardet-Biedl Syndrome (Haqq et al.) (opens in a new tab)(n=44)PubMed (opens in a new tab)PubMed
- [3]Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial (Lancet Diabetes Endocrinol 2025) (opens in a new tab)(n=12)PubMed (opens in a new tab)PubMed
- [4]Real-world efficacy and safety of setmelanotide in adults with monogenic or syndromic obesity: a prospective cohort study (Mifsud et al., Obesity 2025) (opens in a new tab)(n=17,)PubMed (opens in a new tab)PubMed
Additional References
- Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome (Haws et al., Diabetes Obes Metab 2020) (opens in a new tab)PubMed 32627316PubMed
- IMCIVREE (setmelanotide) prescribing information and Instructions for Use, DailyMed, April 2026 (opens in a new tab)FDA Label
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Setmelanotide?
Emerging. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 20–30. Community mentions on Reddit: <20–30 threads estimated (ultra-rare patient population).
150 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.